04/20/2026
Most breakthrough ideas don’t fail because the science is wrong—they stall because the early questions go unanswered.
☑️ Is the unmet need significant and well-defined?
☑️ Where does this solution fit in the clinical workflow?
☑️ What are the regulatory and reimbursement pathways?
☑️ What evidence will be required to move forward?
☑️ And critically: is this idea worth pursuing?
For the past five years, John Morriss, Director of Fogarty Innovation's Invention Acceleration Program (IAP), and engineer-in-residence Bernie Andreas, have worked side-by-side with researchers and clinicians to pressure-test and de-risk promising ideas by answering these questions at the earliest stage. Through structured validation, market analysis, and expert mentorship, the partnership program helps innovators determine not just how to move forward—but whether they should.
The result: stronger foundations, smarter decisions, and a clearer path from concept to company.
Learn how IAP, together with partners like Stanford Biodesign, is transforming early ideas into real ventures:
Many breakthrough medical technologies begin with a moment of insight. A clinician encounters a persistent problem in patient care and develops an idea for a better solution. Or a researcher develops a new technology and realizes it could transform how disease is diagnosed or treated. But promising....